Table 1:
Patient Characteristics and Associations with Folate Receptor Alpha (FRα) Status
| Characteristic | LGSC (total n=89) | FRα-negative (n=53) | FRα-high (n=36) | P-value1 | SBT (total n=42) | FRα-negative (n=33) | FRα-high (n=9) | P-value1 |
|---|---|---|---|---|---|---|---|---|
| %FRα-positive cells (median, range) | 60.1% (0.0–100.0%) | 24.1% (0.0–72.9%) | 85.5% (77.5%–100.0%) | 21.0% (0.0–93.2%) | 12.2% (0.0–73.4%) | 83.0% (75.0%-93.2%) | ||
| Age at diagnosis, y (median, range) | 51 (15–85) | 51 (23–78) | 51 (15–85) | .71 | 54 (20–79) | 49 (20–79) | 60 (38–71) | .034 |
| Race/ethnicity, n (%) | Test not done * | Test not done * | ||||||
| White, non-Hispanic | 70 (83%) | 41 (59%) | 29 (41%) | 37 (90%) | 29 (78%) | 8 (22%) | ||
| Asian | 7 (8%) | 4 (57%) | 3 (43%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
| Black, non-Hispanic | 3 (4%) | 3 (100%) | 0 (0%) | 2 (5%) | 2 (100%) | 0 (0%) | ||
| White, Hispanic | 4 (5%) | 3 (75%) | 1 (25%) | 2 (5%) | 1 (50%) | 1 (50%) | ||
| Missing | 5 | 2 | 3 | 1 | 1 | 0 | ||
| Stage, n (%) | .19 | >.99 | ||||||
| I/II | 7 (8%) | 3 (43%) | 4 (57%) | 30 (71%) | 23 (77%) | 7 (23%) | ||
| III | 64 (73%) | 36 (56%) | 28 (44%) | 12 (29%) | 10 (83%) | 2 (17%) | ||
| IV | 17 (19%) | 13 (76%) | 4 (24%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
| Missing | 1 | 1 | 0 | 0 | 0 | 0 | ||
| Residual disease at primary surgery, n (%) | .36 | Test not done * | ||||||
| Complete gross resection | 47 (60%) | 28 (60%) | 19 (40%) | 35 (83%) | 27 (77%) | 8 (23%) | ||
| Optimal resection (≤ 1 cm) | 24 (31%) | 17 (71%) | 7 (29%) | 6 (14%) | 5 (83%) | 1 (17%) | ||
| Suboptimal resection (> 1 cm) | 7 (9.0%) | 3 (43%) | 4 (57%) | 1 (2%) | 1 (100%) | 0 (0%) | ||
| Missing | 11 | 5 | 6 | 0 | 0 | 0 | ||
| MAPK pathway alteration, n (%) | <.001 | .018 | ||||||
| Absent | 33 (42%) | 13 (39%) | 20 (61%) | 4 (13%) | 1 (25%) | 3 (75%) | ||
| Present | 45 (58%) | 36 (80%) | 9 (20%) | 26 (87%) | 23 (88%) | 3 (12%) | ||
| Missing | 11 | 4 | 7 | 12 | 9 | 3 | ||
| BRAF-V600E mutation, n (%) | .042 | .024 | ||||||
| Wildtype | 71 (91%) | 42 (59%) | 29 (41%) | 17 (57%) | 11 (65%) | 6 (35%) | ||
| Mutant | 7 (9%) | 7 (100%) | 0 (0%) | 13 (43%) | 13 (100%) | 0 (0%) | ||
| Missing | 11 | 4 | 7 | 12 | 9 | 3 |
1
Wilcoxon rank sum test; Fisher exact test.
*
Test not done: P value not provided if patient count ≤3.
LGSC, low-grade serous ovarian carcinoma; FRα, folate receptor alpha; SBT, serous borderline tumor; MAPK, mitogen-activated protein kinase.